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Background: Topical application of corticosteroids also has 
an influence on skin barrier impairment. Physiological lipid 
mixtures, such as multi- lamellar emulsion (MLE) containing 
a natural lipid component leads to effective recovery of the 
barrier function. Objective: The purpose of this study was to 
conduct an evaluation of the therapeutic efficacy and skin 
barrier protection of topical mometasone furoate in MLE. 
Methods: A multi-center randomized, double-blind, con-
trolled study was performed to assess the efficacy and safety 
of mometasone furoate cream in MLE for Korean patients 
with eczema. The study group included 175 patients with ec-
zema, who applied either mometasone furoate in MLE cream 
or methylprednisolone aceponate cream for 2 weeks. Trea-
tment efficacy was evaluated using the physician’s global 
assessment of clinical response (PGA), trans-epidermal 
water loss (TEWL), and visual analogue scale (VAS) for 
pruritus. Patients were evaluated using these indices at days 
4, 8, and 15. Results: Comparison of PGA score, TEWL, and 
VAS score at baseline with those at days 4, 8, and 15 of 
treatment showed a significant improvement in both groups. 
Patients who applied mometasone furoate in MLE (74.8%) 
showed better results (p＜0.05) than those who applied 
methylprednisolone aceponate (47.8%). The TEWL impro-
vement ratio was higher in the mometasone furoate in MLE 
group than that in the methylprednisolone aceponate group, 
and VAS improvement was also better in the mometasone 
furoate in MLE group. Conclusion: Mometasone furoate in 
MLE has a better therapeutic efficacy as well as less skin 
barrier impairment than methylprednisolone aceponate.  
(Ann Dermatol 25(1) 17∼22, 2013)
-Keywords-
Ceramide, Corticosteroid, Eczema, Multi-lammelar emulsion, 
Skin-barrier
INTRODUCTION
Topical steroids are an important and common treatment 
modality for eczematous skin disorders. The choice of to-
pical steroid varies based on skin disease severity, poten-
cy, and delivery vehicle used. Appropriate use of a topical 
steroid makes it possible to treat an eczematous disorder 
effectively. However, they are many notable side effects 
such as skin atrophy, acneiform eruptions, hypertrichosis, 
hypopigmentation, and development of a cutaneous infec-
tion. Such topical glucocorticoid side effects make many 
patients hesitant to use topical steroids. 
Efforts to minimize the side effects of topical steroids have 
been attempted. One approach is to develop novel ste-
roids such as non-halogenated double-ester-type gluco-
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corticoids1. Another technique is to use topical steroid 
together with an anti-atrophogenic substance2. In parti-
cular, topical materials that not only minimize side effects 
of topical steroid but enhance the physiological lipid 
mixture have been investigated.
Another important aspect of eczema treatment is nor-
malizing the defective skin barrier, because impaired skin 
barrier function is an important factor in the pathogenesis 
of eczema. Skin barrier function is affected by multiple 
factors, including downregulation of filaggrin and loco-
grin, reduced ceramide levels, increased proteolytic en-
zyme levels, and enhanced trans-epidermal water loss 
(TEWL)3. The epidermal barrier is composed of a com-
bination of corneocytes and intercellular lipids4,5. The 
stratum corneum (SC) provides a mechanical protection to 
the skin. It functions as a barrier to water loss and per-
meation of soluble substances from the environment. Re-
gulation of permeability, desquamation, antimicrobial 
peptide activity, toxin exclusion, and selective chemical 
absorption are all primary functions of the extracellular 
lipid matrix. In contrast, mechanical reinforcement, hydra-
tion, cytokine-mediated initiation of inflammation, and 
protection from ultraviolet (UV) damage are all provided 
by corneocytes. Among various factors, hydrophobic in-
tercellular lipids are the most important factor for skin 
barrier function, and diminished ceramides create a leaky 
barrier. Particularly in the case of atopic dermatitis (AD), 
abnormal barrier function results from disruption of the 
multi-lamellar structure due to a significant reduction in 
the amount of intercellular lipid ceramides in the SC6-8. 
A disrupted skin barrier can be replenished by a phy-
siological lipid mixture. Multi-lamellar emulsions (MLEs) 
containing pseudoceramide has a multi-lamellar structure 
similar to intercellular lipids of the SC9. Lee et al.9 
reported that patients with AD treated only with a MLE 
improved more than those applying a commercial moi-
sturizing cream in an objective assessment and subjective 
satisfaction scores for symptoms and signs. Ahn et al.10 
reported on a co-application of MLE for topical steroid- 
protected skin barrier function, reinforcing the skin barrier 
permeability. Topical application of ceramides results in 
restoration of barrier function by reducing TEWL9. Effec-
tive enhancement of skin barrier function with a physio-
logical lipid mixture has been reported recently. Chamlin 
et al.11 reported on alleviation of childhood AD using a 
ceramide-dominant, barrier-repair lipid, and attributed the 
improvement seen in their patients to a normalization of 
barrier function, which in turn dampened the cytokine 
cascade that initiates and sustains AD.
Mometasone furoate is a potent topical steroid with pro-
ven efficacy, similar to betametasone12,13. Mometasone fu-
roate contains hexylene glycol, which has antimicrobial 
properties. The effects of hexylene glycol on microor-
ganisms may potentially be beneficial for treating ecze-
matous disorders, with effects on microorganisms, possi-
bly leading to better treatment and a longer relapse-free 
period14. It is also a safe and effective method for a long- 
term use to treat chronic, recurrent disease.
This study was performed to evaluate the clinical efficacy 
of this physiological lipid mixture as a vehicle of mome-
tasone furoate in patients with eczema. We designed a 
multi-center, randomized, double-blind controlled assess-
ment to compare mometasone furoate in MLE with me-
thylprednisolone aceponate. 
MATERIALS AND METHODS
Patients
Patients with eczema and moderate to severe mani-
festations were enrolled. All patients showed eczematous 
skin lesions, presenting symmetrically. Patients ＜4 years 
old were excluded. The following patients were also 
excluded from the study: patients currently undergoing 
treatment with systemic glucocorticoids, antibiotics or 
immunosuppressive agents; those treated with UV radi-
ation; those with other chronic non-eczematous skin 
diseases; those with infectious dermatoses, chronic me-
dical illness such as diabetes; those pregnant or lactating; 
those with skin lesions involving the face or genital area; 
and those with other severe dermatoses or scars. We used 
a wash-out period for patients who had undergone treat-
ment with topical and systemic corticosteroids. Patients 
taking a systemic corticosteroid had a wash-out period of 
4 weeks. Patients who applied a topical corticosteroid had 
a wash-out period of 1 week. This study was approved by 
the Institutional Review Boards at Incheon St. Mary’s 
Hospital, Kangnam Sacred Heart Hospital, Seoul National 
University Hospital, Severance Hospital, and Kwandong 
University Myongji Hospital.
Study design
After informed consent was obtained, the patients were 
randomly assigned to apply mometasone furorate in MLE 
on one side and apply methylprednisolone aceponate on 
the other side. The topically applied formulations were 
mometasone furoate in MLE and methylprednisolone 
aceponate. Together on each randomly assigned side, 
mometasone furoate in MLE was applied on one side for 2 
weeks, and methylprednisolone aceponate was applied 
on the other side for 2 weeks. Mometasone furoate in MLE 
or methylprednisolone aceponate was applied topically to 
skin lesions once daily by all subjects.
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Table 1. Base demographic characteristics of the study group
Age 32.32±19.86
Sex
  Male  76 (47.80)
  Female  83 (52.20)
Past skin disease history
  Yes  25 (15.72)
  No 134 (84.28)
Topical drug allergy history
  Yes -
  No 159 (100.0)
Values are presented as mean±standard deviation or number (%).
Table 2. Baseline results of PGA, TEWL, and VAS score
Mometasone furorate
in MLE (N=159)
Methylprednisolone
aceponate
(N=159)
PGA 7.46±3.11 7.51±3.18
TEWL 33.73±22.47 33.05±21.96
VAS 5.83±2.31 5.99±2.29
Values are presented as mean±standard devation. PGA: physi-
cian’s global assessment of clinical response, TEWL: trans- 
epidermal water loss, VAS: visual analog scale, MLE: multi- 
lamellar emulsion.
The study included a baseline visit before treatment, and 
on days 1, 4, 8, and 15 after treatment initiation. Patients 
were observed and assessed by one physician on days 1, 
4, 8, and 15 throughout the trial. The physician’s global 
assessment of clinical response (PGA) score was adopted 
for an objective assessment of the clinical response to 
treatment. The PGA index was calculated from scales of 
erythema, vesiculation, pruritus, and burning/pain. Each 
parameter was judged on a 0∼3 scale: 0=no symptoms, 
1=mild, 2=moderate, and 3=severe. Clinical efficacy 
was assessed by the PGA improvement ratio. The PGA 
improvement ratio was calculated as:  
PGA improvement ratio (%)=[(PGAday1-PGAdayn)/PGAday1] 
×100 (%)
The TEWL was measured by TewameterⓇ to evaluate 
epidermal permeability barrier function (Courage & Kha-
zaka, Cologne, Germany) on days 1, 4, 8, and 15. Clinical 
efficacy of the improved skin barrier function was assessed 
by the TEWL improvement ratio. The TEWL improvement 
ratio was calculated as: 
TEWL improvement ratio (%)=[(TEWLday1-TEWLdayn)/ TEWLday1] 
×100 (%)
In addition, improvement of pruritus after treatment was 
assessed subjectively, using 10 visual analog scales that 
the patients scored. The visual analogue scale (VAS) 
improvement ratio was calculated as: 
VAS improvement ratio (%)=[(VASday1-VASdayn)/VASday1] 
×100 (%)
All adverse events were recorded, and whether they were 
treatment related or not was also noted.　
Statistical analysis
Mcnemar’s t-test was used to compare the PGA impro-
vement ratio on days 1, 4, 8, and 15 of treatment. p＜0.05 
were regarded as statistically significant. A paired t-test 
and the Wilcoxon signed-rank test were used to verify 
significant differences in TEWL and VAS scores between 
groups A and B during the follow-up period. 
RESULTS
Summary of patients
A total of 175 patients were initially enrolled. Fifteen 
patients were excluded due either to violation of protocols 
or adverse reactions, and one patient was excluded due to 
a screening criteria violation. In total, 159 patients were 
analyzed (76 males and 83 females; age range, 5∼79 
years; mean age, 32.32±19.86, mean±standard deviation 
years old). No clinically significant differences were obser-
ved in the PGA score, TEWL, or VAS between the mome-
tasone furoate in MLE group and the methylprednisolone 
aceponate group. Basal demographic characteristics of the 
study groups and basal results of the PGA, TEWL, and VAS 
scores are summarized in Table 1 and 2.
Clinical efficacy of mometasone furoate in MLE
We performed a data analysis on patients who completed 
15 days of treatment to assess efficacy. Comparison of the 
PGA score improvement ratio at baseline with days 4, 8, 
and 15 of treatment showed a significant increase for all 
follow-up periods. At baseline, the mean PGA score was 
7.46±3.11 in the mometasone furoate in MLE group and 
7.51±3.18 in the methylprednisolone group. After 15 
days, the PGA improvement ratio in the mometasone 
furoate in MLE group was 82.62±21.62%, and that in the 
methylprednisolone acetonate group was 68.32±24.05% 
(p≤0.0001). The PGA improvement ratio for days 4, 8, 
and 15 is summarized in Fig. 1.
TEWL improvement in the mometasone furoate in MLE 
group
At baseline, the baseline TEWL score in the mometasone 
furoate in MLE group was 33.73±22.47 g/h/m2 and 33.05 
±21.96 g/h/m2 in the methylprednisolone acetonate group. 
No significant difference was observed between the 
groups. After 15 days of treatment, the TEWL impro-
vement ratio increased in both groups for all follow-up 
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Fig. 1. The physician’s global assessment of clinical response 
(PGA) improvement ratio at day 4, 8, 15. Comparison of the PGA
improvement ratio between themometasone furoate in multi- 
lamella emulsion (MLE) group and the methylprednisolone group.
A significant difference was observed in the PGA improvement
ratio at all follow-up periods (p≤0.0001).
Fig. 3. The visual analog scale (VAS) improvement ratio. Com-
parison of the VAS improvement ratio between the mometasone
furorate in multi-lamella emulsion (MLE) group and the methyl-
prednisolone group. A significant difference was observed in the
VAS improvement ratio at day 15 (p≤0.0001).
Fig. 2. The trans-epidermal water loss (TEWL) improvement ratio. 
Comparison of the TEWL improvement ratio between the mome-
tasone furorate in multi-lamella emulsion (MLE) group and the me-
thylprednisolone group. A significant difference was observed in 
the TEWL improvement ratio at all follow-up periods (p≤0.0001).
periods. After 15 days of treatment in the mometasone 
furoate in MLE group, the TEWL improvement ratio, whi-
ch was 48.30±68.04% at baseline, was statistically signi-
ficant; and in the methylprednisolone acetonate group, the 
TEWL improvement ratio increased 32.74±50.07% from 
baseline after 15 days. Although the TEWL improvement 
ratio increased in both groups, the TEWL improvement 
ratio in the mometasone furoate in MLE group was 
superior to that in the methylprednisolone acetonate 
group (p≤0.0001). The TEWL improvement ratio for days 
4, 8, and 15 is summarized in Fig. 2. The intergroup 
differences were statistically significant at every point. 
VAS improvement in the mometasone furoate in MLE 
group
The subjective VAS score was measured at every visit to 
evaluate improvement of pruritus. The initial VAS score was 
5.83±2.31 in the mometasone furoate in MLE group and 
5.99±2.29 in the methylprednisolone aceponate group 
(p＞0.05). The VAS improvement ratio increased in both 
groups for all follow-up periods. After 15 days of treatment, 
the VAS improvement ratio score increased 83.28±23.47% 
from baseline in the mometasone furoate in MLE group and 
75.41±27.24% in the methylprednisolone group.
In addition, pruritus showed a more significant improve-
ment in the mometasone furoate in MLE group than that in 
the methylprednisolone group (p≤0.0001). The VAS 
improvement ratio at days 4 and 8 also showed an increase 
from baseline; however, no statistically significant inter- 
group difference was observed (p=0.2117, p=0.1131). The 
VAS improvement ratio on days 4, 8, and 15 is sum-
marized in Fig. 3. The difference was statistically signi-
ficant at day 15 (p≤0.0001).
Adverse effects
An itching sensation was observed in two patients (1.15%) 
who applied mometasone furoate in MLE and in 4 patients 
(2.30%) who applied methylprednisolone aceponate. Urti-
caria was observed in one patient (0.57%). Herpes virus 
infection was observed in one patient (0.57%) at a non- 
applied site. Five patients were excluded from the study 
due to pruritus and urticaria.
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DISCUSSION
Both mometasone furoate in MLE and methylprednisolone 
aceponate were effective treatments for eczema. Statisti-
cally significant differences in the PGA score were ob-
served between the values at baseline and at day 15 of tre-
atment. Patients who applied mometasone furoate in MLE 
showed better results in the PGA improvement ratio than 
those who applied methylprednisolone aceponate. Both 
agents are potent group II corticosteroids, and they had 
shown similar efficacy in previous studies. However, 
mometasone furoate in MLE showed superior efficacy, 
likely due to the effects of the physiological lipid mixture 
on enhanced skin barrier function.
This was supported by the results showing TEWL impro-
vement, as it mirrors the skin barrier function. The TEWL 
improvement ratio was also higher in those who applied 
mometasone furoate in MLE. Prolonged treatment with a 
topical steroid creates structural defects in the epidermis, 
which has been attributed to a disturbance in epidermal 
differentiation and thinning of the SC10. A disrupted skin 
barrier due to abnormalities in intercellular lipid lamellae, 
which are thought to mediate transcutaneous water loss, 
results in an increase in TEWL score10. The VAS impro-
vement ratio was higher with the physiological lipid mix-
ture. Applying mometasone furoate in MLE resulted in 
significant improvement in clinical symptoms and signs of 
eczematous disorder. Subjectively, patients felt less of an 
itching sensation over the treatment period.
Topical corticosteroids not only have antiproliferative eff-
ects but also suppress differentiation of the epidermal 
layer, resulting in defects in the epidermis10. Therefore, 
long-term use of topical glucocorticoid causes weakening 
of the skin barrier. Many studies have been performed to 
minimize the side effects of glucocorticoids. One attempt 
involves reinforcing the skin barrier function using a phy-
siological lipid mixture. Man MQ et al.15 reported that 
topical application of a physiological lipid mixture results 
in accelerated recovery of barrier function, whereas an 
incomplete lipid mixture may inhibit the normal recovery 
response. Additionally, topical application of an MLE 
containing a pseudoceramide results in significantly 
decreased TEWL and skin pH16. Ahn et al.10 reported that 
concurrent application of MLE with steroid significantly 
reduces skin atrophy induced by steroid.
The physiological lipid mixture using a vehicle allows for 
the penetration of topical steroid into the skin and enhan-
ces delivery. Mometasone furorate in MLE showed a more 
beneficial effect than that of methylprednisolone acepo-
nate, which has similar potency but not the physiological 
lipid mixture. As such, the treatment period for a topical 
steroid would be shortened using the same potency. The 
side effects of topical steroids are dependent on duration 
and frequency of application17. It is possible that the lower 
steroid potency causes similar effects to a higher potency 
steroid. We suggest that a physiological lipid mixture as a 
topical steroid vehicle enhances the effects of a topical 
steroid and diminishes the side effects.
Use of moisturizers is an important treatment method to 
improve skin hydration, even when overt disease is not 
observed. Daily treatment with topical moisturizers pre-
vents exacerbation of skin lesions by reducing elevated 
TEWL. The MLE-containing moisturizers are effective for 
hydration of eczema and have a safety profile9. A phy-
siological lipid mixture using pseudoceramides is present-
ed in an orthorhombic lipid phase, which chiefly exists on 
the human SC lipid, while non-physiological lipid mixture 
moisturizers only show a liquid crystalline phase and a 
hexagonal phase. An increase in TEWL results in skin de-
hydration, and xerosis cutis itself aggravates eczematous 
disease and makes pruritus more severe. 
Pruritus, the most common and important symptom of an 
eczematous skin disorder, causes a vicious itching- scrat-
ching cycle. Therefore, rapid amelioration of pruritus sho-
rtens disease duration and enhances treatment compli-
ance. In recent studies, a physiological lipid mixture using 
pseudoceramides not only restored the skin barrier but 
also had an anti-inflammatory effect. Kang et al.18 reported 
that topical application of MLE using pseudoceramides 
results in diminished mRNA expression of interleukin (IL)- 
4 and tumor necrosis factor-α in murine atopic derma-
titis-like skin lesions. IL-4 and IL-13 play a major role in 
allergic reactions. A suppressed immune response dimini-
shes the cytokine cascade involved in the pathogenesis of 
pruritus.
In our study, only a few local side effects were observed 
such as pruritus and urticaria. The intensity of the itching 
sensation was mild, and the duration was a few hours to a 
day. As such, local side effects rarely required disconti-
nuation of treatment. 
In conclusion, mometasone furoate in MLE was a more 
effective treatment for moderate to severe skin eczema 
than that of methylprednisolone. As mometasone furoate 
in MLE induced improvement in skin barrier function, and 
we recommend more studies using of physiological lipid 
mixtures as a vehicle for topical therapeutic agents.
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